

#### **Financial Statements**

Year Ended December 31, 2020

# Drug Prevention Resources, Inc. Table of Contents December 31, 2020

Independent Auditor's Report	1
Financial Statements Statement of Financial Position.	3
Statement of Activities	4
Statement of Functional Expenses	5
Statement of Cash Flows	6
Notes to Financial Statements	7
Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	13
Independent Auditor's Report on Compliance for Each Major Program and on Internal Control Over Compliance Required by the Uniform Guidance	15
Schedule of Expenditures of Federal and State Awards	17
Notes to Schedule of Expenditures of Federal and State Awards	18
Schedule of Findings and Questioned Costs	19
Schedule of Prior Year Findings and Questioned Costs	20

#### Founding Partners

John S. Brock, CPA
Jake Froemsdorf, CPA
Jaye Gasaway, CPA
Rocky Goodman, CPA
Robert Greg Schichtl, II, CPA
J. Michael Tuohev, CPA



Partners Emeritus
M. John Borchert, CPA
Richard S. McIlroy, CPA

Bentonville | Conway | Hot Springs | Little Rock 501 North University Ave. | Little Rock, AR 72205 | 501.280.0222 | garlandandgreenwood.com

#### **Independent Auditor's Report**

To the Board of Directors Drug Prevention Resources, Inc. Dallas, Texas

#### **Report on the Financial Statements**

We have audited the accompanying financial statements of Drug Prevention Resources, Inc. (a nonprofit organization), which comprise the statement of financial position as of December 31, 2020, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

#### Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

#### Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion.

An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### **Opinion**

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Drug Prevention Resources, Inc. as of December 31, 2020, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

#### **Other Matters**

Other Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal and state awards, as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

#### Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 31, 2021, on our consideration of Drug Prevention Resources, Inc.'s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Drug Prevention Resources, Inc.'s internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Drug Prevention Resources, Inc.'s internal control over financial reporting and compliance.

## Garland & Greenwood, CPAs and Advisors, PLLC

Little Rock, Arkansas December 31, 2021

## Statement of Financial Position December 31, 2020

#### **Assets**

Current Assets		
Cash	\$	61,904
Grants receivable		78,198
Other current assets		815
Total Current Assets		140,917
Property and Equipment, net		8,786
Other Assets		2,250
Total Assets	\$	151,953
Liabilities and Net Assets  Current Liabilities		
Current maturities of long-term debt	\$	_
Accounts payable and accrued expenses	*	22,396
Accrued compensated absences		26,727
Total Current Liabilities		49,123
Long-Term Liabilities		185,600
Total Liabilities		234,723
Net Assets		
With donor restrictions		9,894
Without donor restrictions		(92,664)
Total Net Assets		(82,770)
<b>Total Liabilities and Net Assets</b>	\$	151,953

## Statement of Activities For the Year Ended December 31, 2020

Revenues and Support	Net Assets Without Donor Restrictions		Vithout Donor With Donor		 Total
Grants and contributions					
Individuals and corporate	\$	65,296	\$	-	\$ 65,296
Grants		972,676		-	972,676
Investment return		-		-	-
Other		16,382			 16,382
Total Revenues and Support		1,054,354		-	1,054,354
Expenses Program services Management and general		993,521 173,780		-	993,521 173,780
Fundraising		69,398			 69,398
Total Expenses		1,236,699			 1,236,699
Change in Net Assets		(182,345)		-	(182,345)
Net Assets, Beginning of Year		89,681		9,894	 99,575
Net Assets, End of Year	\$	(92,664)	\$	9,894	\$ (82,770)

## Statement of Functional Expenses For the Year Ended December 31, 2020

	Program Services		Management and General		ndraising	Total Expenses		
Salaries and related	\$ 814,936	\$	50,450	\$	40,098	\$	905,484	
General and administrative	3,316		28,189		1,659		33,164	
Travel and business	24,145		2,683		-		26,828	
Professional fees	37,423		37,422		-		74,845	
Marketing	5,518		5,517		11,035		22,070	
Depreciation expense	13,339		826		656		14,821	
Supplies	23,419		18,735		4,684		46,838	
Rent	45,302		9,060		6,041		60,403	
Office expenses	 26,123		20,898		5,225		52,246	
	\$ 993,521	\$	173,780	\$	69,398	\$	1,236,699	

## Statement of Cash Flows For the Year Ended December 31, 2020

Cash Flows From Operating Activities	
Change in net assets	\$ (182,345)
Adjustments to reconcile change in net assets	
to net cash used by operating activities:	
Depreciation expense	14,821
Realized and unrealized (gains)/losses on investments	
(Increase)/Decrease in assets:	
Grants receivable	10,928
Other current assets	1,584
Other assets	3,925
Increase/(Decrease) in liabilities	
Accounts payable and accrued expenses	15,656
Accrued compensated absences	 (14,600)
Net Cash Used by Operating Activities	 (150,031)
Cash Flows from Investing Activities	
Capital expenditures	 (6,867)
Net Cash Provided by Investing Activities	 (6,867)
Cash Flows from Financing Activities	
Proceeds from long-term debt	185,600
Net Cash Provided by Investing Activities	185,600
Net Change in Cash	28,702
Cash, Beginning of Year	 33,202
Cash, End of Year	\$ 61,904

Notes to Financial Statements December 31, 2020

#### **Note 1: Nature of Organization**

Drug Prevention Resources, Inc. (the "Organization") is the oldest drug prevention organization in Texas, celebrating 86 years of service in 2021. The Organization is a not-for-profit substance abuse prevention organization with a mission dedicated to preventing youth substance abuse through innovative delivery of evidence-based strategies that empower youth, families, and communities to flourish within their environments. The Organization accomplishes this by providing individual strategies for high-risk youth and environmental strategies in high risk neighborhoods. The Organization is supported primarily through federal grants, state grants, and donor contributions.

#### **Note 2: Summary of Significant Accounting Policies**

#### Basis of Presentation

The financial statements of the Organization have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"), which require the Organization to report information regarding its financial position and activities according to the following net asset classifications:

#### **Net assets without donor restrictions:**

Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Organization. These net assets may be used at the discretion of Drug Prevention Resources, Inc.'s management and the board of directors.

#### **Net assets with donor restrictions:**

Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of Drug Prevention Resources, Inc. or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statements of activities.

#### Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates.

#### Cash

Drug Prevention Resources, Inc.'s considers all short-term investments with an original maturity of ninety days or less to be cash equivalents. The Organization places its cash, which, at times, may exceed federally insured limits, with high-credit quality institutions. The Organization has not experienced any losses on such accounts.

Notes to Financial Statements December 31, 2020

#### Grants Receivable

Grants receivable consists of amounts billed to federal and state agencies for program expenditures incurred as of year-end for reimbursement. The Organization deems all receivables collectible hence there is no estimated allowance for doubtful accounts.

#### Property and Equipment, net

Property and equipment are stated at cost at the date of purchase or, for donated assets, at fair value at the date of donation, less accumulated depreciation. Depreciation is calculated using the straight-line method over the lessor of the estimated useful lives of the assets or the lease term. The useful lives range from three to seven years. Drug Prevention Resources, Inc.'s policy is to capitalize renewals and betterments acquired for greater than \$5,000 and expense normal repairs and maintenance as incurred. The Organization's management periodically evaluates whether events or circumstances have occurred indicating that the carrying amount of long-lived assets may not be recovered.

#### Grant Revenue

Grant revenue is received from the U.S. Department of Health and Human Services and the Texas Health and Human Services Commission, a pass-through entity for the U.S. Department of Health and Human Services, under a reimbursement contract. This revenue is recorded when earned as net assets without donor restrictions.

#### <u>Individual and Corporate Contributions</u>

Individual and corporate contributions received are recorded as net assets without donor restrictions or net assets with donor restrictions, depending on the existence and/or nature of any donor-imposed restrictions. Contributions that are restricted by the donor are reported as an increase in net assets without donor restrictions if the restriction expires in the reporting period in which the contribution is recognized. All other donor restricted contributions are reported as an increase in net assets with donor restrictions, depending on the nature of restriction. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from restrictions.

#### Functional Expenses

The cost of providing program and other activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the Organization's program activities and supporting services benefited. Such allocations are determined by management on an equitable basis.

#### Income Taxes

Drug Prevention Resources, Inc. is exempt from income tax under IRC section 501(c)(3), though it is subject to tax on income unrelated to its exempt purpose. Drug Prevention Resources, Inc. has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. Drug Prevention Resources, Inc. has determined that there are no material uncertain tax positions that require recognition or disclosure in the financial statements.

Notes to Financial Statements December 31, 2020

#### Recent Accounting Pronouncements

The following accounting standards are future changes in accounting principles and will go into effect in future periods.

Revenue Recognition - The Financial Accounting Standards Board (FASB) amended its standards related to revenue recognition. This amendment replaces all existing revenue recognition guidance and provides a single, comprehensive revenue recognition model for all contracts with customers. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The amendment also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in those judgments and assets recognized from costs incurred to fulfill a contract. The standard allows either full or modified retrospective adoption effective for nonpublic entities for annual periods beginning after December 15, 2019, and any interim periods within annual reporting periods that begin after December 15, 2020. The Organization has adopted the new standard utilizing the modified retrospective adoption for 2020. The adoption of the new standard did not materially change revenue recognition.

Accounting for Leases – FASB amended its standard related to the accounting for leases. Under the new standard, lessees will now be required to recognize substantially all leases on the balance sheets as both a right-of-use asset and a liability. The standard has two types of lease for statements of operations recognition purposes; operating leases and finance leases. Operating leases will result in the recognition of a single lease expense on a straightline basis over the lease term similar to the treatment for operating leases under existing standards. Finance leases will result in an accelerated expense similar to the accounting or capital leases under existing standards. The determination of lease classification as operating or finance will be done in a manner similar to existing standards. The new standard also contains amended guidance regarding the identification of embedded leases in service contracts and the identification of and nonlease components in an arrangement. The new standard is effective for annual periods beginning after December 15, 2021, and any interim periods within annual reporting periods that begin after December 15, 2022. The Organization is evaluating the effect the standard will have on the financial statements; however, the standard is expected to have a material effect on the financial statements due to the recognition of additional assets and liabilities for operating leases.

Notes to Financial Statements December 31, 2020

#### Subsequent Events

The COVID-19 pandemic has developed rapidly in 2020, with a significant number of cases. Measures taken by various governments to contain the virus have affected economic activity. At this stage, the impact on the Organization's business and activities has not been significant, and based on the Organization's experience to date, that is expected to remain the case. The Organization will continue to follow various government policies and advice, as well as continue operations in the best and safest way possible without jeopardizing the health of the Organization's people.

Drug Prevention Resources, Inc. has evaluated subsequent events through December 31, 2021, which is the date the financial statements were available to be issued. Drug Prevention Resources, Inc. is not aware of any material subsequent events.

#### **Note 3: Availability and Liquidity**

The following represents Drug Prevention Resources, Inc.'s financial assets at December 31, 2020:

Financial assets at year-end:

Financial assets at year-end:		
Cash	\$	61,904
Accounts and grants receivable		77,828
Other current assets		815
Total financial assets		140,917
Less amounts not available to be used within one year:  Net assets with donor restrictions		9,894
Total amounts not available to be used within one year	-	9,894
Financial assets available to meet general expenditures		,
over the next twelve months	\$	131,023

Drug Prevention Resources, Inc. is generally to maintain financial assets to meet 30 days of operating expenses (approximately \$125,000). As part of its liquidity plan, excess cash is invested in short-term investments, including money market accounts.

#### **Note 4: Long-term Debt**

On April 17, 2020, the Organization was granted a loan (the "Loan") from Frost Bank for \$185,600, pursuant to the Paycheck Protection Program (the "PPP") of the CARES Act. The loan was dated April 9, 2020 and matures on April 17, 2022. The Note may be prepaid by the borrower at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred before February 15, 2020. The Organization intends to use the entire Loan amount for qualifying expenses. Under terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses.

Notes to Financial Statements December 31, 2020

#### **Note 4: Long-term Debt (continued)**

Subsequent to the date of the financial statements, but prior to the date the financial statements were available to be issued, the Loan was forgiven in its entirety of \$185,600.

In 2021, the Organization received a second draw of the PPP loan in the amount of \$185,600. This loan has substantially the same terms, conditions, and requirements of the first PPP loan. Subsequent to the date of the financial statements, but prior to the date the financial statements were available to be issued, the second PPP loan was forgiven in its entirety of \$185,600.

#### **Note 5: Property and Equipment, Net**

Property and equipment, net consisted of the following at December 31, 2020:

Property and equipment Less: accumulated depreciation	\$ 45,316 (36,530)
Property and equipment, net	\$ 8,786

Property and equipment consisted of equipment and furniture and fixtures. For the year ended December 31, 2020, depreciation expense totaled \$14,821.

#### **Note 6: Lease Commitments**

The Organization leases office space under a noncancelable operating lease agreement expiring on September 30, 2025. Rent expense under these operating leases was approximately \$55,847 for the year ended December 31, 2020.

Required minimum lease payments under the lease agreements are approximately as follows for the years ending December 31,

2021	\$ 40,800
2022	42,900
2023	45,000
2024	47,100
2025	36,900
2026	0
Thereafter	 0
	\$ 212,700

#### **Note 7: Concentration of Risk**

As of December 31, 2020, 100% of the Organization's grants receivable were due from two grantors. For the year ended December 31, 2020, the Organization received approximately 92% of its total support and revenue from two grantors.

### Notes to Financial Statements December 31, 2020

#### **Note 8: Net Assets**

Net assets with donor restrictions for the year ended December 31, 2020 are as follows:

Specific purpose Navarro County Programs	\$ 9,894
Total	\$ 9,894

Net assets without donor restrictions for the year ended December 31, 2020 are as follows:

Undesignated \$ (92,664)

Total \$ (92,664)

There were no net assets released from donor restrictions for the year ended December 31, 2020.

#### Founding Partners

John S. Brock, CPA
Jake Froemsdorf, CPA
Jaye Gasaway, CPA
Rocky Goodman, CPA
Robert Greg Schichtl, II, CPA
J. Michael Tuohev, CPA



Partners Emeritus
M. John Borchert, CPA
Richard S. McIlrov, CPA

Bentonville | Conway | Hot Springs | Little Rock 501 North University Ave. | Little Rock, AR 72205 | 501.280.0222 | garlandandgreenwood.com

# Independent Auditor's Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

To the Board of Directors Drug Prevention Resources, Inc. Dallas, Texas

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Drug Prevention Resources, Inc. (a nonprofit organization), which comprise the statement of financial position as of December 31, 2020, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated December 31, 2021.

#### **Internal Control over Financial Reporting**

In planning and performing our audit of the financial statements, we considered Drug Prevention Resources, Inc.'s internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Drug Prevention Resources, Inc.'s internal control. Accordingly, we do not express an opinion on the effectiveness of the Drug Prevention Resources, Inc.'s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements, on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Government Audit Quality Center Employee Benefit Plan Audit Quality Center

#### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether Drug Prevention Resources, Inc.'s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

#### **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the organization's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the organization's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Garland & Greenwood, CPAs and Advisors, PLLC

Little Rock, Arkansas December 31, 2021

#### Founding Partners

John S. Brock, CPA
Jake Froemsdorf, CPA
Jaye Gasaway, CPA
Rocky Goodman, CPA
Robert Greg Schichtl, II, CPA
J. Michael Tuohev, CPA



Partners Emeritus
M. John Borchert, CPA
Richard S. McIlroy, CPA

Bentonville | Conway | Hot Springs | Little Rock 501 North University Ave. | Little Rock, AR 72205 | 501.280.0222 | garlandandgreenwood.com

## Independent Auditor's Report on Compliance for Each Major Program and on Internal Control Over Compliance Required by the Uniform Guidance

To the Board of Directors Drug Prevention Resources, Inc. Dallas, Texas

#### Report on Compliance for Each Major Federal Program

We have audited Drug Prevention Resources, Inc.'s compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of Drug Prevention Resources, Inc.'s major federal programs for the year ended December 31, 2020. Drug Prevention Resources, Inc.'s major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

#### Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal and state awards applicable to its federal programs.

#### Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of Drug Prevention Resources, Inc.'s major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Drug Prevention Resources, Inc.'s compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Drug Prevention Resources, Inc.'s compliance.

#### Opinion on Each Major Federal Program

In our opinion, Drug Prevention Resources, Inc. complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2020.

#### **Report on Internal Control over Compliance**

Management of Drug Prevention Resources, Inc. is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Drug Prevention Resources, Inc.'s internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Drug Prevention Resources, Inc.'s internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Garland & Greenwood, CPAs and Advisors, PLLC

Little Rock, Arkansas December 31, 2021

### Schedule of Expenditures of Federal and State Awards For the Year Ended December 31, 2020

		Federal CFDA			
Federal or State Grantor/Pass-Through Grantor/Program Title		Number	Name of Grant/ Grant ID #	Exp	oenditures
Federal:	_				
Department of Health and Human Services					
Passed Through Texas Health and Human Services Commission					
Block Grants for Prevention and Treatment of Substance Abuse	*	93.959	Youth Prevention - Universal/ HHS000539700033		167,622
Block Grants for Prevention and Treatment of Substance Abuse	*	93.959	Youth Prevention - Selective/ HHS000539700091		154,675
Block Grants for Prevention and Treatment of Substance Abuse	*	93.959	Community Coalition Partnerships/ HHS000539700137		117,866
Block Grants for Prevention and Treatment of Substance Abuse	*	93.959	Community Coalition Partnerships/ HHS000539700138		77,371
Block Grants for Prevention and Treatment of Substance Abuse	*	93.959	Community Coalition Partnerships/ HHS000539700140		117,461
Block Grants for Prevention and Treatment of Substance Abuse	*	93.959	Community Coalition Partnerships/ HHS000539700141		119,134
Total Block Grants for Prevention and Treatment of Substance Abuse					754,129
Total Passed Through Texas Health and Human Services Commission	l				754,129
Total Expenditures of Federal Awards				\$	754,129
State:					
General Revenue:					
Texas Health and Human Services Commission		N/A	Youth Prevention - Universal/ HHS000539700033	\$	7,000
Texas Health and Human Services Commission		N/A	Youth Prevention - Selective/ HHS000539700091		4,042
Texas Health and Human Services Commission		N/A	Community Coalition Partnerships/ HHS000539700138		81
Texas Health and Human Services Commission		N/A	Community Coalition Partnerships/ HHS000539700140		2,478
<b>Total Expenditures of State General Revenues</b>				\$	13,601
Total Expenditures of Federal Awards and State General Revenues				\$	767,730

<sup>\*</sup>indicates major program

See accompanying notes to schedule of expenditures of federal and state awards.

Notes to Schedule of Expenditures of Federal and State Awards For the Year Ended December 31, 2020

#### **Note 1: Basis of Presentation**

The accompanying schedule of expenditures of federal and state awards includes the federal and state grant activity of Drug Prevention Resources, Inc. and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and Texas Governor's Office of Budget and Planning, Uniform Grant Management Standards, which include the State of Texas Single Audit Circular (UGMS). Because the schedules present only a selected portion of the operations of Drug Prevention Resources, Inc., they are not intended to and do not present the financial position, changes in net assets or cash flows of Drug Prevention Resources, Inc.

#### **Note 2: Indirect Costs**

Expenditures on the schedule of expenditures of federal and state awards are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Drug Prevention Resources, Inc. has elected not to use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.

#### Schedule of Findings and Questioned Costs December 31, 2020

#### I. Summary of Auditor's Results

- 1. We have issued an unmodified opinion on the financial statements of Drug Prevention Resources, Inc. as of and for the year ended December 31, 2020.
- 2. No material weaknesses relating to the audit of the financial statements were found.
- 3. No significant deficiencies relating to the audit of the financial statements were found.
- 4. The results of the financial statement audit disclosed no instances of noncompliance which were considered material to the financial statements.
- 5. We issued an unmodified opinion in our report on compliance for major programs for the year ended December 31, 2020.
- 6. No significant deficiencies relating to the audit of internal control over major federal award programs were found.
- 7. There were no audit findings that are required to be reported in accordance with OMB Uniform Guidance 200.516(a).
- 8. The program tested as a major program for the year ended December 31, 2020 is as follows:

Cluster/Program CFDA Number
Block Grants for Prevention and Treatment of Substance Abuse 93.959

- 9. The threshold used for distinguishing between type A and B programs was \$750,000.
- 10. Drug Prevention Resources, Inc. did not qualify as a low-risk auditee.

## II. Findings Relating to the Financial Statements Reported in Accordance with Government Auditing Standards

None.

## III. Findings and Questioned Costs Relating to Federal Awards

None

Drug Prevention Resources, Inc. Schedule of Prior Year Findings and Questioned Costs December 31, 2020

No matters are reportable.